Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a
clinical-stage biotechnology company developing a new generation of
targeted antitumor virotherapies, announced a $2 million strategic
investment by Dr. Ronald Rigor into its new subsidiary, Nova Cell,
Inc. (“Nova Cell”), to advance Calidi’s Adult Adipose Allogeneic
(AAA) stem cell innovative programs. Dr Rigor also invested an
additional $1 million into Calidi to further its oncology pipeline
of assets.
Dr. Ronald Rigor, an accomplished Board-Certified Dermatologist,
Internal Medicine, and Stem Cell Therapy expert with offices in Los
Angeles, CA USA and Metro Manila, Philippines (BGC), has taken a
significant step to advance regenerative medicine by investing in
Calidi’s new Nova Cell subsidiary. The investment comprises of (i)
a $1 million dollar subscription agreement to purchase a
combination of CLDI common stock at a 10% discount to the closing
price on July 22, 2024 and warrants to purchase 600,000 shares of
common stock at a 20% premium to the closing price on July 22,
2024; and (ii) a $2 million dollar investment to purchase common
stock of Nova Cell. Based on Calidi’s advanced cellular
manufacturing process, this investment will unlock the potential of
off-the-shelf AAA stem cells. Furthermore, in connection with
Dr. Rigor’s investment, Calidi is proud to announce his appointment
as a member of its Scientific and Medical Advisory Board.
With reasonable rights of first refusal, Dr. Rigor also receives
an exclusive license to purchase and use the AAA stem cell line in
the Philippines for regenerative purposes and to administer
Calidi’s CLD-201 product (Super Nova platform addressing multiple
solid tumors) for clinical investigations or commercial use in the
Philippines. Furthermore, with reasonable rights of first refusal,
Dr. Rigor has agreed that Nova Cell will be his exclusive
technology service provider to develop innovative stem cell-based
products, such as anti-aging creams and lotions, for sale in the
Philippines.
Calidi started harvesting the AAA stem cells from healthy adult
donors five years ago, adhering to FDA guidelines, for its cancer
platform, CLD-201 (SuperNova). Today, through its new subsidiary,
Nova Cell, the company is now expanding potential uses from
oncology to other fields that require regenerative medical
applications, such as cosmetics, orthopedics, auto-immune diseases,
and various other therapies.
“According to Precedence Research, the global stem cell therapy
market is rapidly growing and estimated to reach $14.5 billion in
2024 and grow to $31.4 billion by 2030. Our AAA stem cell
technology will have the potential to lead this market. Our
proprietary cell expansion method and specialized media, developed
by Calidi’s scientists and process development team, will offer
significant scalability advantages over other mesenchymal stem cell
lines,” said Allan Camaisa, Co-Founder, Chairman, and CEO of Calidi
Biotherapeutics. “We are genuinely excited to have Dr. Rigor
partner with our team of talented scientists at Nova Cell.
Together, we share a common belief that stem cell clinics will be
the next frontier in wellness and health, bringing the regenerative
properties of AAA stem cells and extending and improving overall
quality of life. Nova Cell plans to begin generating revenue by
supplying AAA stem cells to Dr. Rigor for his patients in
2025.”
“As the founder of one of the largest and fastest growing stem
cell centers in the Philippines, I am delighted to partner with and
invest in Nova Cell. This is a fantastic opportunity to provide
best-in-class stem cell therapy treatments which could meet a huge
unmet need in the Philippines,” said Dr. Ronald Rigor. “We look
forward to bringing Nova Cell’s extensive experience in stem cell
therapy production to provide innovative therapies to patients and
to elevate the health and wellness industry in the
Philippines.”
Nova Cell enables Calidi to unlock a valuable asset in AAA stem
cells, generating current and future value. Establishing Nova Cell
as a new subsidiary will also enhance the strategic focus and
resource allocation efficiency for both Calidi, which is dedicated
to cancer therapies, and Nova Cell, which concentrates on
innovative regenerative treatments and other conditions utilizing
stem cells.
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage
immuno-oncology company with proprietary technology designed to arm
the immune system to fight cancer. Calidi’s novel stem cell-based
platforms are utilizing potent allogeneic stem cells capable of
carrying payloads of oncolytic viruses for use in multiple oncology
indications, including high-grade gliomas and solid tumors.
Calidi’s clinical stage off-the-shelf, universal cell-based
delivery platforms are designed to protect, amplify, and potentiate
oncolytic viruses leading to enhanced efficacy and improved patient
safety. Calidi’s preclinical off-the-shelf enveloped virotherapies
are designed to target disseminated solid tumors. This dual
approach can potentially treat, or even prevent, metastatic
disease. Calidi Biotherapeutics is headquartered in San Diego,
California. For more information, please
visit www.calidibio.com.
Forward-Looking Statements
This press release may contain forward-looking statements for
purposes of the “safe harbor” provisions under the United States
Private Securities Litigation Reform Act of 1995. Terms such as
“anticipates,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intends,” “may,” “might,” “plan,” “possible,”
“potential,” “predicts,” “project,” “should,” “towards,” “would” as
well as similar terms, are forward-looking in nature, but the
absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include, but are
not limited to, statements concerning upcoming key milestones
(including the reporting of interim clinical results and the dosing
of patients), planned clinical trials, and statements relating to
the safety and efficacy of Calidi’s therapeutic candidates in
development. Any forward-looking statements contained in this
discussion are based on Calidi’s current expectations and beliefs
concerning future developments and their potential effects and are
subject to multiple risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth or
implied in such forward-looking statements. These risks and
uncertainties include, but are not limited to, the risk that Calidi
is not able to raise sufficient capital to support its current and
anticipated clinical trials, the risk that early results of
clinical trials do not necessarily predict final results and that
one or more of the clinical outcomes may materially change
following more comprehensive review of the data, and as more
patient data becomes available, the risk that Calidi may not
receive FDA approval for some or all of its therapeutic candidates.
Other risks and uncertainties are set forth in the section entitled
“Risk Factors” and “Cautionary Note Regarding Forward-Looking
Statements” in the Company’s Registration Statements filed with the
SEC on Form S-4 filed on August 2, 2023, on Form S-1 filed on
October 6, 2023, on Form S-1 filed on January 29, 2024, as amended
on February 7, 2024, on Form 10-K filed on March 15, 2024, and
Final Prospectus filed on April 17, 2024.
For Investors and Media:
Stephen Thesing
IR@Calidibio.com
Calidi Biotherapeutics (AMEX:CLDI)
과거 데이터 주식 차트
부터 9월(9) 2024 으로 10월(10) 2024
Calidi Biotherapeutics (AMEX:CLDI)
과거 데이터 주식 차트
부터 10월(10) 2023 으로 10월(10) 2024